Zac Germon Profile
Zac Germon

@ZacGermon

Followers
114
Following
333
Statuses
63

Post Doctoral Scientist @ University of Newcastle | Cell Signalling | Proteomics | Leukaemia + DIPG | CSRG #DunLab

Joined September 2019
Don't wanna be here? Send us removal request.
@ZacGermon
Zac Germon
3 months
@MattDun17 @charles_debock @NatureComms @KidsCancerInst I have! Amazing data, congrats to all involved.
0
0
1
@ZacGermon
Zac Germon
4 months
@Ritchlynn_A @TheASMR1 Thanks Ritch!
0
0
0
@ZacGermon
Zac Germon
6 months
@MattDun17 @Mika_Persson97 @RUNDIPG Congratulations Mika!!
0
0
3
@ZacGermon
Zac Germon
8 months
Thanks Heather, looking forward to it!
@Dr_Heather_Lee
Heather Lee
8 months
On July 18, I'll be hosting @XuDongZhang15 and @ZacGermon at an online seminar for @AEpiA. I'm looking forward to showcasing the work of two great colleagues from @UON_research and @HMRIAustralia . Tune in for some fabulous science and discussion!
Tweet media one
0
0
7
@ZacGermon
Zac Germon
8 months
@DavidSkerrettB @nhmrc Great news, congratulations David!
0
0
1
@ZacGermon
Zac Germon
11 months
Thanks @CancerAustralia & @KidsCancerProj! Excited to be given the opportunity to continue this project investigating much needed novel treatment strategies for Paediatric cancers #AML #DMG #DIPG
@MattDun17
Matt Dun, PhD
11 months
Delighted #DunLab 's childhood cancer project was funded by @CancerAustralia & @KidsCancerProj Free-radicals (#ROS) promote cancer signaling in RTK mutant- #AML & #DMG #DIPG Here we will develop new targeted treatments Congrats @ZacGermon @duchatel_ryan @Jonatha16752881 DE & ID
1
2
10
@ZacGermon
Zac Germon
11 months
RT @MattDun17: Wonderful to see the glossy version & cover of #DunLab’s latest paper discovering the genetic dependency & targeting of PI3K…
0
14
0
@ZacGermon
Zac Germon
1 year
@williamreay96 Congratulations Will! All the best in Tassy!
0
0
0
@ZacGermon
Zac Germon
1 year
Congratulations @MattDun17! So well deserved. Your dedication and determination inspire us each day in the fight against kids cancer!
@MattDun17
Matt Dun, PhD
1 year
So thankful to receive this prestigious award on behalf of our incredible #DunLab team May I thank all our #CSRG team & recognise the inspirational scientists that did all the work particularly @evierjackson @duchatel_ryan @AliciaD0uglas @DilanaStaudt @ZacGermon #DIPG 💪 @RUNDIPG
0
0
7
@ZacGermon
Zac Germon
1 year
RT @MattDun17: What a team #DunLab 2023-2024
Tweet media one
0
5
0
@ZacGermon
Zac Germon
1 year
Congrats, Sam and team! A super interesting review. Thank you for the opportunity to contribute.
@Dr_Heather_Lee
Heather Lee
1 year
Our new review on #hypoxia and #DNAmethylation in #AML is online today. We explored complex and bi-directional interactions between hypoxia signalling and regulation of DNA methylation as well as implications for AML therapy.
Tweet media one
0
0
5
@ZacGermon
Zac Germon
1 year
0
0
1
@ZacGermon
Zac Germon
2 years
@Bryce_Thomas23 @DilanaStaudt @MattDun17 @VitanzaNick @michelle_monje Congrats Bryce and team, on a great paper and an awesome image!
0
0
2
@ZacGermon
Zac Germon
2 years
@MattDun17 @PrecisionMedUON @UON_research Thanks Matt, and thank you for all the support and opportunities you have given me along the way. To be continued!
0
0
6
@ZacGermon
Zac Germon
2 years
Congrats Evie and team! Great summary of this paper below.
@evierjackson
Evie Jackson
2 years
Incredibly proud to share the latest work from #DunLab, published in #CancerResearch! We highlight the combination of ONC201 and paxalisib for the treatment of DMG, the preclinical data informing PNOC022. Follow this tweetorial for a summary: (1/10)
0
0
6
@ZacGermon
Zac Germon
2 years
RT @scisignal: A new study shows that inhibiting the oxidase NOX2 suppresses a common subtype of #AcuteMyeloidLeukemia (AML) in mice by blo…
0
4
0
@ZacGermon
Zac Germon
2 years
RT @MattDun17: Probably my favourite part of adding to the literature, students/stuff pinning their first author papers to our walls of hon…
0
6
0
@ZacGermon
Zac Germon
2 years
Excited to see this paper published today in @scisignal. This work formed a large part of my PhD and is summarised below:
@MattDun17
Matt Dun, PhD
2 years
#DunLab paper alert: Patients diagnosed with the most common driver mutation in acute myeloid leukemia (AML) – FLT3, are associated with poor-outcomes. FLT3+ AML sees the overproduction of reactive oxygen species (ROS), a second messenger signaling (T1)
5
5
18
@ZacGermon
Zac Germon
2 years
RT @MattDun17: Access to new drugs in paediatric oncology: can we learn from the ongoing ONC201 saga? ⁦@TheLancetOncol#DunLab, #CSRG@UO
0
15
0